Title

非酒精性脂肪肝病之肝外系統疾病

Translated Titles

Extra-Hepatic Manifestations of Non-Alcoholic Fatty Liver Disease

DOI

10.6320/FJM.202205_26(3).0007

Authors

許景盛(Ching-Sheng Hsu)

Key Words

非酒精性脂肪肝 ; 代謝症候群 ; 心血管疾病 ; 預後 ; 標準治療 ; non-alcoholic fatty liver disease ; metabolic syndrome ; cardiovascular diseases ; prognosis ; standard of care

PublicationName

台灣醫學

Volume or Term/Year and Month of Publication

26卷3期(2022 / 05 / 25)

Page #

328 - 335

Content Language

繁體中文

Chinese Abstract

非酒精脂肪肝病患者常伴隨有代謝異常的問題,因此臨床上常見到患者,會同時伴隨有許多代謝異常有關的肝外系統疾病,包括肥胖症、糖尿病、血脂異常、代謝症候群、心血管疾病、慢性腎臟疾病、癌症、多囊性卵巢症候群、甲狀腺機能低下症、阻塞型睡眠呼吸中止症、骨質疏鬆症、肌少症與乾癬等。臨床證據顯示,肝外系統疾病與非酒精性脂肪肝病不但臨床關係密切,並且會互相影響,部分肝外系統疾病,甚至可能影響非酒精性脂肪肝病患者的預後以及死亡。所以臨床上面對非酒精性脂肪肝病患者時,除了治療肝臟疾病本身以外,還需要同時處理這些肝外系統疾病對病人可能造成的各種風險及傷害,包括給予患者一般常規建議的體重控制、調整及改變飲食與運動習慣,以及針對各種肝外系統疾病的評估與處置。因此結合各種肝外系統疾病的評估與治療,將成為非酒精性脂肪肝病患者,臨床醫療照護上的重要核心,使治療照護變得更全面性、更深入性、更個人化以及更精準化。本文將針對目前臨床上較重要、常見,並且已累積有較多臨床實證支持著,與非酒精性脂肪肝病關聯的肝外系統疾病,做簡單的介紹與說明。

English Abstract

Patients with non-alcoholic fatty liver diseases are often accompanied by metabolic abnormalities and various extrahepatic systemic diseases, including obesity, diabetes, dyslipidemia, metabolic syndrome, cardiovascular diseases, chronic kidney diseases, cancers, polycystic ovary syndrome, hypothyroidism, obstructive sleep apnea, osteoporosis, sarcopenia, and psoriasis. Current evidence shows that extrahepatic systemic diseases and non-alcoholic fatty liver disease are not only closely related clinically but also interact with each other. Some extrahepatic systemic diseases may affect the clinical prognosis, outcomes, and death of patients with non-alcoholic fatty liver disease. Therefore, when managing patients with non-alcoholic fatty liver diseases, we need to manage the liver disease per se and the associated various injuries and risks accompanying extrahepatic system diseases. In addition to the general recommendations for body weight control, and the adjustment for diet and exercise habits, the assessment and treatment of various extrahepatic systemic diseases will become an important part of the standard of care for patients with nonalcoholic fatty liver diseases. Combining the evaluation and treatment of various extrahepatic systemic diseases not only will improve the quality of treatment and care for patients with non-alcoholic fatty liver diseases, but also make the management more comprehensive, in-depth, personalized, and precise. In this article, I will briefly introduce some clinically common and important extrahepatic systemic diseases that are frequently associated with non-alcoholic fatty liver diseases.

Topic Category 醫藥衛生 > 醫藥衛生綜合
Reference
  1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64.
    連結:
  2. Wang H, Mehal W, Nagy LE, et al. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91.
    連結:
  3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
    連結:
  4. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, Is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10.
    連結:
  5. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019;71: 793-801.
    連結:
  6. Tada T, Toyoda H, Sone Y, et al. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2019;34:2011-8.
    連結:
  7. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016;65:589-600.
    連結:
  8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
    連結:
  9. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11: e1001680.
    連結:
  10. Jang HR, Kang D, Sinn DH, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep 2018;8:4718.
    連結:
  11. Kim D, Adejumo AC, Yoo ER, et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology 2019;157: 1055-66.e11
    連結:
  12. Allen AM, Hicks SB, Mara KC, et al. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol 2019;71: 1229-36.
    連結:
  13. Wu J, Yao XY, Shi RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health 2018;15:77.
    連結:
  14. Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int 2020;40:355-9.
    連結:
  15. Chung GE, Kim D, Kim W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012;57:150-6.
    連結:
  16. Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol 2018;16:123-31.e1.
    連結:
  17. Tanne F, Gagnadoux F, Chazouilleres O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005;41:1290-6.
    連結:
  18. Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath 2018;22:841-51.
    連結:
  19. Pirgon O, Bilgin H, Tolu I, et al. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2011;75:189-95.
    連結:
  20. Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 2012;97: 2033-8.
    連結:
  21. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2017;66:123-31.
    連結:
  22. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51: 758-64.
    連結:
  23. Phan K, Onggo J, Charlton O, et al. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis. Australas J Dermatol 2019;60:e352-5.
    連結:
  24. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-8.
    連結:
  25. Linares I, Hamar M, Selzner N, et al. Steatosis in liver transplantation: current limitations and future strategies. Transplantation 2019;103:78-90.
    連結: